AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?
Identifieur interne : 001912 ( Pmc/Corpus ); précédent : 001911; suivant : 001913AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?
Auteurs : Leslie A. Reperant ; Albert D. M. E. OsterhausSource :
- Vaccine [ 0264-410X ] ; 2017.
Abstract
Emerging infections have threatened humanity since times immemorial. The dramatic anthropogenic, behavioral and social changes that have affected humanity and the environment in the past century have accelerated the intrusion of novel pathogens into the global human population, sometimes with devastating consequences. The AIDS and influenza pandemics have claimed and will continue to claim millions of lives. The recent SARS and Ebola epidemics have threatened populations across borders. The emergence of MERS may well be warning signals of a nascent pandemic threat, while the potential for geographical spread of vector-borne diseases, such as Zika, but also Dengue and Chikungunya is unprecedented. Novel technologies and innovative approaches have multiplied to address and improve response preparedness towards the increasing yet unpredictable threat posed by emerging pathogens.
Url:
DOI: 10.1016/j.vaccine.2017.04.082
PubMed: 28633891
PubMed Central: 7115365
Links to Exploration step
PMC:7115365Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?</title><author><name sortKey="Reperant, Leslie A" sort="Reperant, Leslie A" uniqKey="Reperant L" first="Leslie A." last="Reperant">Leslie A. Reperant</name><affiliation><nlm:aff id="af005">Artemis One Health Research Foundation, Utrecht, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation><nlm:aff id="af005">Artemis One Health Research Foundation, Utrecht, The Netherlands</nlm:aff></affiliation><affiliation><nlm:aff id="af010">Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28633891</idno><idno type="pmc">7115365</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115365</idno><idno type="RBID">PMC:7115365</idno><idno type="doi">10.1016/j.vaccine.2017.04.082</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">001912</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001912</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?</title><author><name sortKey="Reperant, Leslie A" sort="Reperant, Leslie A" uniqKey="Reperant L" first="Leslie A." last="Reperant">Leslie A. Reperant</name><affiliation><nlm:aff id="af005">Artemis One Health Research Foundation, Utrecht, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation><nlm:aff id="af005">Artemis One Health Research Foundation, Utrecht, The Netherlands</nlm:aff></affiliation><affiliation><nlm:aff id="af010">Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany</nlm:aff></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><idno type="eISSN">1873-2518</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Emerging infections have threatened humanity since times immemorial. The dramatic anthropogenic, behavioral and social changes that have affected humanity and the environment in the past century have accelerated the intrusion of novel pathogens into the global human population, sometimes with devastating consequences. The AIDS and influenza pandemics have claimed and will continue to claim millions of lives. The recent SARS and Ebola epidemics have threatened populations across borders. The emergence of MERS may well be warning signals of a nascent pandemic threat, while the potential for geographical spread of vector-borne diseases, such as Zika, but also Dengue and Chikungunya is unprecedented. Novel technologies and innovative approaches have multiplied to address and improve response preparedness towards the increasing yet unpredictable threat posed by emerging pathogens.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Reperant, L A" uniqKey="Reperant L">L.A. Reperant</name></author><author><name sortKey="Cornaglia, G" uniqKey="Cornaglia G">G. Cornaglia</name></author><author><name sortKey="Osterhaus, A D M E" uniqKey="Osterhaus A">A.D.M.E. Osterhaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Waters, C N" uniqKey="Waters C">C.N. Waters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sanders, J W" uniqKey="Sanders J">J.W. Sanders</name></author><author><name sortKey="Fuhrer, G S" uniqKey="Fuhrer G">G.S. Fuhrer</name></author><author><name sortKey="Johnson, M D" uniqKey="Johnson M">M.D. Johnson</name></author><author><name sortKey="Riddle, M S" uniqKey="Riddle M">M.S. Riddle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Swart, R L" uniqKey="De Swart R">R.L. de Swart</name></author><author><name sortKey="Duprex, W P" uniqKey="Duprex W">W.P. Duprex</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gao, F" uniqKey="Gao F">F. Gao</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Barre Sinoussi, F" uniqKey="Barre Sinoussi F">F. Barre-Sinoussi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dalgleish, A G" uniqKey="Dalgleish A">A.G. Dalgleish</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Borducchi, E N" uniqKey="Borducchi E">E.N. Borducchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reperant, L A" uniqKey="Reperant L">L.A. Reperant</name></author><author><name sortKey="Kuiken, T" uniqKey="Kuiken T">T. Kuiken</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dawood, F S" uniqKey="Dawood F">F.S. Dawood</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Hancock, K" uniqKey="Hancock K">K. Hancock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Clark, T W" uniqKey="Clark T">T.W. Clark</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greenberg, M E" uniqKey="Greenberg M">M.E. Greenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, H" uniqKey="Chen H">H. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liang, X F" uniqKey="Liang X">X.F. Liang</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Kiley, M P" uniqKey="Kiley M">M.P. Kiley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olival, K J" uniqKey="Olival K">K.J. Olival</name></author><author><name sortKey="Hayman, D T" uniqKey="Hayman D">D.T. Hayman</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Chappell, K J" uniqKey="Chappell K">K.J. Chappell</name></author><author><name sortKey="Watterson, D" uniqKey="Watterson D">D. Watterson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, J S" uniqKey="Peiris J">J.S. Peiris</name></author><author><name sortKey="Yuen, K Y" uniqKey="Yuen K">K.Y. Yuen</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author><author><name sortKey="Stohr, K" uniqKey="Stohr K">K. Stohr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drosten, C" uniqKey="Drosten C">C. Drosten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fouchier, R A" uniqKey="Fouchier R">R.A. Fouchier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, W" uniqKey="Li W">W. Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, H D" uniqKey="Song H">H.D. Song</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, W" uniqKey="Li W">W. Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haagmans, B L" uniqKey="Haagmans B">B.L. Haagmans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, J T" uniqKey="Lin J">J.T. Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martin, J E" uniqKey="Martin J">J.E. Martin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name></author><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name></author><author><name sortKey="Bestebroer, T M" uniqKey="Bestebroer T">T.M. Bestebroer</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author><author><name sortKey="Fouchier, R A" uniqKey="Fouchier R">R.A. Fouchier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raj, V S" uniqKey="Raj V">V.S. Raj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, Q" uniqKey="Wang Q">Q. Wang</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Haagmans, B L" uniqKey="Haagmans B">B.L. Haagmans</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Smalley, C" uniqKey="Smalley C">C. Smalley</name></author><author><name sortKey="Erasmus, J H" uniqKey="Erasmus J">J.H. Erasmus</name></author><author><name sortKey="Chesson, C B" uniqKey="Chesson C">C.B. Chesson</name></author><author><name sortKey="Beasley, D W" uniqKey="Beasley D">D.W. Beasley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hayes, E B" uniqKey="Hayes E">E.B. Hayes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Broutet, N" uniqKey="Broutet N">N. Broutet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tripp, R A" uniqKey="Tripp R">R.A. Tripp</name></author><author><name sortKey="Ross, T M" uniqKey="Ross T">T.M. Ross</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cleaveland, S" uniqKey="Cleaveland S">S. Cleaveland</name></author><author><name sortKey="Laurenson, M K" uniqKey="Laurenson M">M.K. Laurenson</name></author><author><name sortKey="Taylor, L H" uniqKey="Taylor L">L.H. Taylor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sims, L D" uniqKey="Sims L">L.D. Sims</name></author><author><name sortKey="Peiris, M" uniqKey="Peiris M">M. Peiris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khan, S U" uniqKey="Khan S">S.U. Khan</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccine</journal-id><journal-id journal-id-type="iso-abbrev">Vaccine</journal-id><journal-title-group><journal-title>Vaccine</journal-title></journal-title-group><issn pub-type="ppub">0264-410X</issn><issn pub-type="epub">1873-2518</issn><publisher><publisher-name>Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28633891</article-id><article-id pub-id-type="pmc">7115365</article-id><article-id pub-id-type="publisher-id">S0264-410X(17)30583-2</article-id><article-id pub-id-type="doi">10.1016/j.vaccine.2017.04.082</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Reperant</surname><given-names>Leslie A.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Osterhaus</surname><given-names>Albert D.M.E.</given-names></name><email>Albert.Osterhaus@tiho-hannover.de</email><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="af005"><label>a</label>Artemis One Health Research Foundation, Utrecht, The Netherlands</aff><aff id="af010"><label>b</label>Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany</aff><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author at: Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany. <email>Albert.Osterhaus@tiho-hannover.de</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>19</day><month>6</month><year>2017</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><day>16</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>19</day><month>6</month><year>2017</year></pub-date><volume>35</volume><issue>35</issue><fpage>4470</fpage><lpage>4474</lpage><permissions><copyright-statement>© 2017 Published by Elsevier Ltd.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder></copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab005"><p>Emerging infections have threatened humanity since times immemorial. The dramatic anthropogenic, behavioral and social changes that have affected humanity and the environment in the past century have accelerated the intrusion of novel pathogens into the global human population, sometimes with devastating consequences. The AIDS and influenza pandemics have claimed and will continue to claim millions of lives. The recent SARS and Ebola epidemics have threatened populations across borders. The emergence of MERS may well be warning signals of a nascent pandemic threat, while the potential for geographical spread of vector-borne diseases, such as Zika, but also Dengue and Chikungunya is unprecedented. Novel technologies and innovative approaches have multiplied to address and improve response preparedness towards the increasing yet unpredictable threat posed by emerging pathogens.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Emerging</kwd><kwd>Epidemics</kwd><kwd>Virus</kwd><kwd>Preparedness</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Main text</title><p id="p0005">Ever since the emergence of the human species from the animal world, complex interactions between humans and animals have resulted in human-animal interfaces that promoted cross-species transmission, emergence and evolution of an ever increasing number of human pathogens, originating from animals (review in <xref rid="b0005" ref-type="bibr">[1]</xref>). In the past centuries, our global environment has changed dramatically as a result of major and unprecedented anthropogenic influences that have had a significant and global impact on the earth's ecosystems <xref rid="b0005" ref-type="bibr">[1]</xref>. These influences include extreme forms of predatory behavior, domestication, warfare, colonization, travel, agriculture, habitat fragmentation, urbanization and industrialization, collectively leading to what has now been proposed to be the most recent geological period: the ‘Anthropocene’ <xref rid="b0010" ref-type="bibr">[2]</xref>. Until the beginning of the last century, infectious diseases were the major cause of human mortality, causing about fifty percent of all human deaths. In the following decades, this burden dramatically decreased to less than a few percent in the industrialized world <xref rid="b0015" ref-type="bibr">[3]</xref>. Implementation of public health measures such as sewage installment and development of clean drinking water systems, but also to introduction of vaccines and antimicrobials were the major drivers of this spectacular decrease. Successes in this regard were the eradication of smallpox virus and rinderpest virus through orchestrated vaccination campaigns among humans and cattle, respectively. The eradication of smallpox virus led to the abolishment of smallpox vaccination, which created a niche for human infections with other orthopox viruses, leading to increasing incidences of human cowpox and more dramatically monkeypox. The eradication of rinderpest virus from cattle may well bear important lessons for the envisaged eradication of the closely related measles virus from humans through sustained vaccination efforts <xref rid="b0020" ref-type="bibr">[4]</xref>. Both these viruses with a quite similar pathogenesis in their respective species belong to the Morbillivirus genus of which several members have a history of frequent interspecies transmission. This raises the question whether we should continue measles vaccination, even after the eventual eradication of measles virus.</p><p id="p0010">The successful reduction of infectious diseases in the middle of the last century even prompted prominent policymakers and scientists to raise the expectation that infectious diseases of humankind would eventually, at least in the industrialized world, be brought under control. Paradoxically the following decades confronted the world with an ever-increasing number of emerging or re-emerging infectious diseases, some causing true pandemic threats or even pandemics. Viruses spilling over from wildlife reservoirs, either directly or via intermediate hosts, were at the basis of most of these disease outbreaks. Striking examples of emerging viral diseases of mankind that had their origin in wildlife reservoirs and spilled over either directly or via domestic animals, were AIDS from chimpanzees, influenza from wild birds, Ebola, SARS and MERS from bats, and Dengue, Chikungunya and Zika from mosquitoes. This paved the way for the unprecedented spread of infections in humans and animals with dramatic consequences for public and animal health, animal welfare, food supply, economies, and biodiversity.</p><p id="p0015">The <bold>AIDS</bold> pandemic that emerged more than three decades ago, happened after multiple introductions of a simian lentivirus from chimpanzee reservoirs into the human population <xref rid="b0025" ref-type="bibr">[5]</xref>. To date more than 70 million people have become infected, more than 35 million have died, while more than 1 million die annually <xref rid="b0030" ref-type="bibr">[6]</xref>. One of the central questions in this tragic series of events is, why did a lentivirus that has been ‘locked up’ in chimpanzee reservoirs for a long time, suddenly start a human pandemic? A complex mix of predisposing factors linked to major changes in the societal environment and ecology of our globalizing world, collectively created opportunities and niches for HIV to not only cross the animal-human species barrier, but to also spread globally in the new human host. Although huge efforts were made to stop this pandemic, it took more than two years before <bold>HIV</bold> was identified as the causative agent <xref rid="b0035" ref-type="bibr">[7]</xref>, another two years to identify CD4 as its receptor <xref rid="b0040" ref-type="bibr">[8]</xref>, about a decade before an effective antiviral strategy was developed <xref rid="b0045" ref-type="bibr">[9]</xref>, while it is not even clear today if and when a vaccine will become available, despite new hopes making the news <xref rid="b0050" ref-type="bibr">[10]</xref>.</p><p id="p0020">The continuing threat posed by <bold>influenza viruses</bold> in migratory bird reservoirs, that may lead to zoonotic infections via domestic poultry or mammals like pigs, can eventually lead to an influenza pandemic <xref rid="b0055" ref-type="bibr">[11]</xref>. Humanity has experienced four pandemics in the past century, which have collectively cost the lives of tens of millions of people. During the last pandemic - the Mexican flu - that was relatively mild in spite of causing deaths among relatively young people <xref rid="b0060" ref-type="bibr">[12]</xref>, we for the first time could use specific and effective antivirals and vaccines, although for many countries vaccines came too late or in too low quantities. This was in part due to largely outdated manufacturing practices making use of embryonated chicken eggs for the production of the vaccines (reviewed in <xref rid="b0065" ref-type="bibr">[13]</xref>). Clinical preparedness was furthermore limited, with relatively few implementations of relevant clinical studies and trials, at the start and during the course of the pandemic <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>. Such studies are essential to gather evidence on the efficacy of preventive and therapeutic interventions, to inform clinical management and guide public health response. A wide diversity of avian influenza viruses with zoonotic potential are circulating in poultry and wild bird reservoirs, posing an abiding threat to humanity. Recent outbreaks of highly pathogenic and low pathogenic avian influenza virus infections in poultry and wild birds across Asia, Europe and Africa this winter demonstrate an ever-present Sword of Damocles. Therefore the influenza vaccine community is now concentrating on the development of more universal influenza vaccines, with broader coverage and longer longevity of protection against a wide range of influenza virus strains and subtypes <xref rid="b0095" ref-type="bibr">[19]</xref>.</p><p id="p0025"><bold>Ebola</bold> was first identified as a disease entity associated with high mortality, in the seventies of the last century <xref rid="b0100" ref-type="bibr">[20]</xref>. It was eventually recognized that the most likely reservoir of the causative filovirus is bats, based on serology, PCR and experimental infections <xref rid="b0105" ref-type="bibr">[21]</xref> and that the virus may infect humans upon bat contacts, or upon consumption of e.g. primates that have died as a result of the infection acquired from bats. Since the infection initially occurred in urban regions where human-to-human transmission routes could rapidly be understood and avoided, the annual Ebola death toll was always less than 1000 people during outbreaks. Although efforts to develop a vaccine against Ebola viruses were made, they never went beyond pre-clinical testing in macaques. When during the last and devastating Ebola outbreak that started in 2013, the virus started to spread in urban environments of West Africa and subsequently through air travel to many other countries worldwide, the global death toll rose to more than 11,000 individuals. Limited diagnostic capacity largely contributed to the delayed recognition of the emerging epidemic, with initial cases misdiagnosed as cholera and later as Lassa fever <xref rid="b0110" ref-type="bibr">[22]</xref>. The delayed recognition of the Ebola outbreak led to overwhelmed health care systems unable to contain the spread of the virus. Halted vaccine development and testing activities were resumed but relatively late during the course of the epidemic, and eventually the epidemic was contained by strict implementation of hygienic and sanitary measures <xref rid="b0115" ref-type="bibr">[23]</xref>. However, several Ebola vaccine candidates and prime-boost regimens were tested pre-clinically and eventually also clinically in the affected area. The trials were initiated mostly during the tail of the epidemic, but led to at least one effective vaccine <xref rid="b0115" ref-type="bibr">[23]</xref>. This vaccine may be used in the face of a next Ebola outbreak, to protect healthcare workers and contacts of infected individuals, to control nosocomial and subsequent further spread in the population.</p><p id="p0030"><bold>Severe acute respiratory syndrome (SARS)</bold> was recognized as a disease entity when clusters of atypical pneumonia were identified in provincial hospitals in China at the end of 2002 from where it spread to Hong Kong. This subsequently led to a global outbreak by dissemination of the virus through air travel. In total, more than 8000 people were infected, with 774 deaths reported in 37 countries <xref rid="b0120" ref-type="bibr">[24]</xref> (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). Once the search for the cause was started by a WHO-coordinated task force consisting of representatives of a dozen laboratories worldwide, within two weeks SARS coronavirus (SARS-CoV) was identified as the etiologic agent and the Koch’s postulates were fulfilled <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>. Angiotensin converting enzyme 2 (ACE2) was identified as its functional receptor within months after the new virus discovery <xref rid="b0135" ref-type="bibr">[27]</xref>. The virus most likely originated from bats and spread to humans via live animal markets in China, where Himalayan civet cats and other carnivores sold for human consumption had become infected <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>. After identification of the agent, implementation of specific diagnostic tests and isolation of infected individuals halted the spread of the virus. Antiviral strategies, like the use of Interferon-α proved effective <xref rid="b0150" ref-type="bibr">[30]</xref>, and a dozen of SARS vaccine candidates were developed. However as the disease was rapidly controlled after the identification of the agent, further development and clinical testing of vaccine candidates were stopped <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>. Collectively the well-coordinated activities that led to the early identification of the virus and the implementation of measures at the global scale limited the death toll of this emerging pandemic.<fig id="f0005"><label>Fig. 1</label><caption><p>Global distribution of reported cases of SARS coronavirus infection at the end of the epidemic of 2003 and of MERS coronavirus infection as of January 2017 (at country level); blue: countries that reported cases of SARS coronavirus infection only; yellow: countries that reported cases of MERS coronavirus infection only; orange: countries that reported both cases of SARS and MERS coronavirus infection. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</p></caption><graphic xlink:href="gr1_lrg"></graphic></fig></p><p id="p0035">Ten years after the emergence of SARS-CoV, another coronavirus was identified as the cause of an emerging respiratory disease in the Middle East; the <bold>Middle East Respiratory Syndrome (MERS)</bold> coronavirus (MERS-CoV). Initially the virus was identified as the cause of a fatal respiratory infection in an elderly man in Saudi Arabia <xref rid="b0165" ref-type="bibr">[33]</xref>, and subsequently CD26 was rapidly identified as the receptor <xref rid="b0170" ref-type="bibr">[34]</xref>. MERS-CoV also likely originated from bats <xref rid="b0175" ref-type="bibr">[35]</xref>, spread via dromedary camels to humans, and proved to cause disease outbreaks in Middle East and Asian hospitals. The total number of confirmed cases is approaching 2000, with a case fatality rate of about 35% <xref rid="b0180" ref-type="bibr">[36]</xref>. From the Middle East the virus has spread to a total of 27 countries where in some cases also chains of human-to-human infections have taken place, e.g., in the Republic of Korea (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). Several vaccine development activities have been initiated and different vaccine candidates have been developed. One of these is an MVA-based vaccine expressing the MERS-CoV glycoprotein. It proved to be efficacious in dromedary camels, while most likely also effective against camelpox <xref rid="b0185" ref-type="bibr">[37]</xref>. This vaccine has prompted discussions on the advantages of prevention at the source, i.e., in the animal reservoir of the disease, supporting the One Health approach increasingly endorsed by the international community. This vaccine will soon be clinically tested in humans, with the final aim of protecting healthcare workers to prevent nosocomial spread, and protecting contacts of infected individuals.</p><p id="p0040">The mosquito-borne infections <bold>Dengue, Chikungunya and Zika</bold> are imminent threats to humanity, in part due to the expansion of their arthropod vectors, in particular <italic>Aedes aegypti</italic> and (<italic>A</italic>.) <italic>albopictus</italic>, into new geographical areas. This is facilitated by anthropogenic changes including climate change. <bold>Dengue</bold> is one of the most common vector-borne diseases, with four distinct serotypes of dengue flavivirus circulating in more than 110 countries worldwide, mainly in tropical and sub-tropical regions (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). Its incidence has increased dramatically in the past decades with half of the world’s population now at risk. Infection may cause severe hemorrhagic fever, especially upon subsequent infections with different dengue flavivirus serotypes. Globally, there may be close to 400 million cases of dengue virus infection annually, with about 100 million clinically symptomatic, and half a million requiring hospitalization <xref rid="b0190" ref-type="bibr">[38]</xref>. It is a leading cause of severe disease and death in children in Asia and South America. Only recently – since late 2015 – was the first dengue vaccine registered (Dengvaxia CYD-TDV by Sanofi Pasteur).<fig id="f0010"><label>Fig. 2</label><caption><p>Current geographical range of sustained transmission of Dengue (A), Chikungunya (B) and Zika (C) virus (at country level).</p></caption><graphic xlink:href="gr2_lrg"></graphic></fig></p><p id="p0045">Historically distributed across tropical Africa and Southeast Asia, the <bold>Chikungunya</bold> alphavirus has in recent years expanded its geographical range across the Indian Ocean and lately across South America and the Caribbean. It has also caused outbreaks in more temperate regions, such as Florida (USA), southern France, Italy and Croatia, evolving from a rare and exotic ailment to a disturbing international public health threat. More than 100 countries and territories are affected by sustained local transmission (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). In contrast to other arbovirus diseases, chikungunya causes acute symptomatic disease in the majority of patients, with about 30% further developing chronic disabling arthralgias. As for other rare and neglected diseases, attempts for the development of chikungunya virus vaccines have so far not led to the successful implementation of effective intervention strategies against this emerging virus infection. A number of vaccines have been developed up to pre-clinical evaluation, with three vaccine candidates having reached up to phase 2 clinical trials <xref rid="b0195" ref-type="bibr">[39]</xref>.</p><p id="p0050">Until recent outbreaks in the Pacific in 2007 and 2013, and its spread to the Americas in 2015, mainly serologic evidence of <bold>Zika</bold> flavivirus infection had been reported in African and Asian countries <xref rid="b0200" ref-type="bibr">[40]</xref>. Less than a hundred cases of infection were confirmed in Micronesia in 2007, while the epidemic of 2013 spread across the Pacific, resulted in an estimated 20,000–35,000 cases, with imported cases in New Caledonia, Japan and Germany. In early 2014, autochthonous Zika virus transmission was reported in New Caledonia, as well as on the Cook Islands and Easter Island (Chile). Cases were later imported to Queensland Australia, Germany and New Zealand. In 2015, autochthonous Zika cases continued to occur in the Pacific, before reaching Brazil and Columbia and further spreading across central and Latin America (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). Asymptomatic infections are likely common, and clinical manifestations include fever with a rash, conjunctivitis and arthralgia. Zika virus is a cause of microcephaly and other congenital brain anomalies, as well as a trigger of Guillain-Barré syndrome <xref rid="b0205" ref-type="bibr">[41]</xref>. It may further be associated with other neurological disorders. A number of Zika virus vaccine candidates are currently being developed <xref rid="b0210" ref-type="bibr">[42]</xref>.</p><p id="p0055">Due to the complex and largely interactive nature of the drivers for newly emerging virus infections, it is virtually impossible to predict what the next pathogen threat will be, from where it will come and when it will strike. The recent Ebola and Zika epidemics testify of the unpredictable nature of emerging infections, yet point to a particularly persistent threat by RNA viruses, likely due to their ability to rapidly evolve and adapt to (environmental and host) changes <xref rid="b0215" ref-type="bibr">[43]</xref>. A better understanding of the underlying processes favoring infectious disease emergence may eventually lead to improved preparedness for outbreaks in humans and animals. Importantly, the increased emergence of viral infections is largely paralleled by medical, veterinary, technological, and scientific progress, continuously spurred by our never-ending drive to combat pathogens. Investment in better understanding the human-animal interfaces will therefore offer a future head start in the never-ending battle against infectious diseases of humans. Comprehensive surveillance programs, based on new high-throughput technologies and improved diagnostic capacity in regions of the world that need them most, constitute the essential foundation upon which preparedness programs can be built. Rapid identification and characterization of novel pathogens and their host-interactions, e.g. with cellular receptors and innate immune responses, is key to allow prompt diagnostic and containment measures, as demonstrated by the emerging SARS pandemic that was essentially nipped in the bud. Prevention at the source and One Health interventions have strong potential to mitigate the threats posed by zoonotic pathogens. Successful examples include the closure of Asian wet-markets, reducing the risk of emergence of zoonotic pathogens, such as influenza A viruses and SARS coronavirus <xref rid="b0220" ref-type="bibr">[44]</xref>. Protection of date palm sap collection by simple measures like bamboo skirts, reduced bat contacts in Bangladesh, limiting the risk of contamination with Nipah virus and other known or unknown bat pathogens <xref rid="b0225" ref-type="bibr">[45]</xref>. Emerging epidemics also offer invaluable but often rarely occurring opportunities to carry out clinical research aimed at improved clinical management and better-informed public health responses. Therefore, clinical preparedness with associated adapted policy, regulatory and ethical procedures are urgently needed for timely deployment upon emerging epidemics. Lastly, the establishment of vaccine and antimicrobial development platforms, widely applicable to both known and still unknown pathogens, while striving towards more universal or broader protective responses, will further contribute to a better R&D based response preparedness towards an ever-increasing threat.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Reperant</surname><given-names>L.A.</given-names></name><name><surname>Cornaglia</surname><given-names>G.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name></person-group><article-title>The importance of understanding the human-animal interface. From early hominins to global citizens</article-title><source>Curr Top Microbiol Immunol</source><volume>365</volume><year>2013</year><fpage>49</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">23042568</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>C.N.</given-names></name></person-group><article-title>The Anthropocene is functionally and stratigraphically distinct from the Holocene</article-title><source>Science</source><volume>351</volume><year>2016</year><fpage>aad2622</fpage><pub-id pub-id-type="pmid">26744408</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>J.W.</given-names></name><name><surname>Fuhrer</surname><given-names>G.S.</given-names></name><name><surname>Johnson</surname><given-names>M.D.</given-names></name><name><surname>Riddle</surname><given-names>M.S.</given-names></name></person-group><article-title>The epidemiological transition: the current status of infectious diseases in the developed world versus the developing world</article-title><source>Sci Prog</source><volume>91</volume><year>2008</year><fpage>1</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">18453281</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>de Swart</surname><given-names>R.L.</given-names></name><name><surname>Duprex</surname><given-names>W.P.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>Rinderpest eradication: lessons for measles eradication?</article-title><source>Curr Opin Virol</source><volume>2</volume><year>2012</year><fpage>330</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">22709518</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F.</given-names></name></person-group><article-title>Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes</article-title><source>Nature</source><volume>397</volume><year>1999</year><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">9989410</pub-id></element-citation></ref><ref id="b0030"><label>6</label><mixed-citation publication-type="other" id="h0030">World_Health_Organization. (ed. World_Health_Organization), 2017.</mixed-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Barre-Sinoussi</surname><given-names>F.</given-names></name></person-group><article-title>Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)</article-title><source>Science</source><volume>220</volume><year>1983</year><fpage>868</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">6189183</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Dalgleish</surname><given-names>A.G.</given-names></name></person-group><article-title>The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus</article-title><source>Nature</source><volume>312</volume><year>1984</year><fpage>763</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">6096719</pub-id></element-citation></ref><ref id="b0045"><label>9</label><mixed-citation publication-type="other" id="h0045">Public_Health_Service, D.o.H.a.H.S., 1987.</mixed-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Borducchi</surname><given-names>E.N.</given-names></name></person-group><article-title>Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys</article-title><source>Nature</source><volume>540</volume><year>2016</year><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">27841870</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Reperant</surname><given-names>L.A.</given-names></name><name><surname>Kuiken</surname><given-names>T.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name></person-group><article-title>Adaptive pathways of zoonotic influenza viruses: from exposure to establishment in humans</article-title><source>Vaccine</source><volume>30</volume><year>2012</year><fpage>4419</fpage><lpage>4434</lpage><pub-id pub-id-type="pmid">22537992</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Dawood</surname><given-names>F.S.</given-names></name></person-group><article-title>Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study</article-title><source>Lancet Infect Dis</source><volume>12</volume><year>2012</year><fpage>687</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">22738893</pub-id></element-citation></ref><ref id="b0065"><label>13</label><mixed-citation publication-type="other" id="h0065">Reperant, L.A., Rimmelzwaan, G. & Osterhaus, A.D.M.E. Recent advances in influenza vaccination. F1000Prime Rep 6, 47- (2014).</mixed-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>K.</given-names></name></person-group><article-title>Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus</article-title><source>N Engl J Med</source><volume>361</volume><year>2009</year><fpage>1945</fpage><lpage>1952</lpage><pub-id pub-id-type="pmid">19745214</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>T.W.</given-names></name></person-group><article-title>Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine</article-title><source>N Engl J Med</source><volume>361</volume><year>2009</year><fpage>2424</fpage><lpage>2435</lpage><pub-id pub-id-type="pmid">19745215</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>M.E.</given-names></name></person-group><article-title>Response to a monovalent 2009 influenza A (H1N1) vaccine</article-title><source>N Engl J Med</source><volume>361</volume><year>2009</year><fpage>2405</fpage><lpage>2413</lpage><pub-id pub-id-type="pmid">19745216</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China</article-title><source>Emerg Infect Dis</source><volume>15</volume><year>2009</year><fpage>1849</fpage><lpage>1850</lpage><pub-id pub-id-type="pmid">19891883</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X.F.</given-names></name></person-group><article-title>Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial</article-title><source>Lancet</source><volume>375</volume><year>2010</year><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">20018364</pub-id></element-citation></ref><ref id="b0095"><label>19</label><mixed-citation publication-type="other" id="h0095">Reperant, L.A., Rimmelzwaan, G.F. & Osterhaus, A.D. Advances in influenza vaccination. F1000Prime Rep 6, 47, 2014.</mixed-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Kiley</surname><given-names>M.P.</given-names></name></person-group><article-title>Filoviridae: a taxonomic home for Marburg and Ebola viruses?</article-title><source>Intervirology</source><volume>18</volume><year>1982</year><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">7118520</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Olival</surname><given-names>K.J.</given-names></name><name><surname>Hayman</surname><given-names>D.T.</given-names></name></person-group><article-title>Filoviruses in bats: current knowledge and future directions</article-title><source>Viruses</source><volume>6</volume><year>2014</year><fpage>1759</fpage><lpage>1788</lpage><pub-id pub-id-type="pmid">24747773</pub-id></element-citation></ref><ref id="b0110"><label>22</label><mixed-citation publication-type="other" id="h0110">Chan, M. in Women in Science Lecture Series (ed. World_Health_Organization) (London School of Hygiene and Tropical Medicine, 2015).</mixed-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>K.J.</given-names></name><name><surname>Watterson</surname><given-names>D.</given-names></name></person-group><article-title>Fighting Ebola: a window for vaccine re-evaluation?</article-title><source>PLoS Pathog</source><volume>13</volume><year>2017</year><fpage>e1006037</fpage><pub-id pub-id-type="pmid">28081225</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Stohr</surname><given-names>K.</given-names></name></person-group><article-title>The severe acute respiratory syndrome</article-title><source>N Engl J Med</source><volume>349</volume><year>2003</year><fpage>2431</fpage><lpage>2441</lpage><pub-id pub-id-type="pmid">14681510</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Drosten</surname><given-names>C.</given-names></name></person-group><article-title>Identification of a novel coronavirus in patients with severe acute respiratory syndrome</article-title><source>N Engl J Med</source><volume>348</volume><year>2003</year><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">12690091</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Aetiology: Koch's postulates fulfilled for SARS virus</article-title><source>Nature</source><volume>423</volume><year>2003</year><fpage>240</fpage><pub-id pub-id-type="pmid">12748632</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H.D.</given-names></name></person-group><article-title>Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human</article-title><source>Proc Nat Acad Sci USA</source><volume>102</volume><year>2005</year><fpage>2430</fpage><lpage>2435</lpage><pub-id pub-id-type="pmid">15695582</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Bats are natural reservoirs of SARS-like coronaviruses</article-title><source>Science</source><volume>310</volume><year>2005</year><fpage>676</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">16195424</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques</article-title><source>Nat Med</source><volume>10</volume><year>2004</year><fpage>290</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">14981511</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.T.</given-names></name></person-group><article-title>Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</article-title><source>Antivir Ther</source><volume>12</volume><year>2007</year><fpage>1107</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">18018769</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>J.E.</given-names></name></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>6338</fpage><lpage>6343</lpage><pub-id pub-id-type="pmid">18824060</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V.S.</given-names></name></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><volume>495</volume><year>2013</year><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name></person-group><article-title>Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26</article-title><source>Cell Host Microbe</source><volume>16</volume><year>2014</year><fpage>328</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">25211075</pub-id></element-citation></ref><ref id="b0180"><label>36</label><mixed-citation publication-type="other" id="h0180">World_Health_Organization, 2017.</mixed-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels</article-title><source>Science</source><volume>351</volume><year>2016</year><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26678878</pub-id></element-citation></ref><ref id="b0190"><label>38</label><mixed-citation publication-type="other" id="h0190">World_Health_Organization, 2017.</mixed-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>C.</given-names></name><name><surname>Erasmus</surname><given-names>J.H.</given-names></name><name><surname>Chesson</surname><given-names>C.B.</given-names></name><name><surname>Beasley</surname><given-names>D.W.</given-names></name></person-group><article-title>Status of research and development of vaccines for chikungunya</article-title><source>Vaccine</source><volume>34</volume><year>2016</year><fpage>2976</fpage><lpage>2981</lpage><pub-id pub-id-type="pmid">27026149</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>E.B.</given-names></name></person-group><article-title>Zika virus outside Africa</article-title><source>Emerg Infect Dis</source><volume>15</volume><year>2009</year><fpage>1347</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">19788800</pub-id></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Broutet</surname><given-names>N.</given-names></name></person-group><article-title>Zika virus as a cause of neurologic disorders</article-title><source>N Engl J Med</source><volume>374</volume><year>2016</year><fpage>1506</fpage><lpage>1509</lpage><pub-id pub-id-type="pmid">26959308</pub-id></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Tripp</surname><given-names>R.A.</given-names></name><name><surname>Ross</surname><given-names>T.M.</given-names></name></person-group><article-title>Development of a Zika vaccine</article-title><source>Expert Rev Vaccines</source><volume>15</volume><year>2016</year><fpage>1083</fpage><lpage>1085</lpage><pub-id pub-id-type="pmid">27212079</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name><surname>Cleaveland</surname><given-names>S.</given-names></name><name><surname>Laurenson</surname><given-names>M.K.</given-names></name><name><surname>Taylor</surname><given-names>L.H.</given-names></name></person-group><article-title>Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence</article-title><source>Philos Trans Roy Soc Lond B Biol Sci</source><volume>356</volume><year>2001</year><fpage>991</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">11516377</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>L.D.</given-names></name><name><surname>Peiris</surname><given-names>M.</given-names></name></person-group><article-title>One health: the Hong Kong experience with avian influenza</article-title><source>Curr Top Microbiol Immunol</source><volume>365</volume><year>2013</year><fpage>281</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">22903569</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S.U.</given-names></name></person-group><article-title>A randomized controlled trial of interventions to impede date palm sap contamination by bats to prevent nipah virus transmission in Bangladesh</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e42689</fpage><pub-id pub-id-type="pmid">22905160</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001912 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001912 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7115365
|texte= AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:28633891" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |